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Abstract 
The   receptor   protein   tyrosine   phosphatase   γ   (Ptprg-RPTPγ)   is   a receptor protein widely 
expressed  in  many  tissues,  including  the  central  nervous  system  (CNS).  Several  RPTPγ  isoforms  
are expressed in the brain during development and in adulthood, but their distribution and role are 
unknown. In this study we investigated the distribution  of  some  RPTPγ  isoforms  in  the  adult  brain  
by using antibodies against the epitopes localized in the C- and in the N-terminal domains of the 
full   length   isoform   of   RPTPγ.   We   found   a   predominant   and   widespread   neuronal   positivity  
throughout the neocortex, hippocampus, striatum and in many nuclei of the brainstem and 
cerebellum. At least 2 distinct isoforms that can co-exist in various compartments in the same cell 
are detectable in different neuron types. Immunopositivity for epitopes located in both the N- and 
C-terminus domains were found in the neuropil of cortical and hippocampal neurons, whereas the 
N-terminal domain positivity was found in the soma, often without colocalization with its C-
terminal counterpart. Among glial cells, some protoplasmic and perivascular astrocytes and the 
cerebellar   Bergmann   glia,   express   RPTPγ.   The   astrocytic   expression   of   RPTPγ   and   putative  
processing isoforms of 120 and 80 kDa increases during neuroinflammation, in particular 24h after 
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LPS treatment. Activated astrocytes were  found  to  be  strongly  positive  for  RPTPγ  also  in  a  mice  
model   of   Alzheimer’s   disease.   Our   results   confirm   previous   findings   and   enrich   the   current  
knowledge   of   RPTPγ   distribution   in   the   CNS,   highlighting   a   role   of   RPTPγ   during  
neuroinflammation processes. 
Key words (4-6):  RPTPγ,  neuroinflammation,  LPS,  RPTPζ,  reactive  astrocytes  and  Alzheimer’s  
disease. 
 
Introduction 
 
It is now well established that in the brain receptor-subtype protein kinases and phosphatases are 
key regulators of signaling mechanisms underlying synaptic network orchestration (Dabrowski 
and Umemori 2011) and neuron-glia interactions (Faissner et al. 2006). While protein tyrosine 
kinases have been extensively studied so far, the role and the functions of receptor protein tyrosine 
phosphatases (RPTPs) are less known (for a review see Tonks 2006). RPTPs are classified into 
distinct groups, on the basis of their structure (Johnson and Van Vactor 2003). The Receptor 
Protein   Tyrosine   Phosphatase   γ   (RPTPγ)   is   a   member   of   the   V   subgroup   of   Receptor   PTPs  
together with its highly homologous PTP zeta (RPTPζ) (Barnea et al. 1993; Nishiwaki et al. 1998). 
The structure of these proteins includes a carbonic anhydrase-like domain and a fibronectin 
domain that together with a spacer region form the extracellular N-terminal portion. The 
intracellular C-terminal portion presents 2 tyrosine phosphatase domains, one of which lacks the 
catalytic activity (Barnea et al. 1993; Lamprianou and   Harroch   2006).   RPTPγ   is   expressed   in  
developing and adult vertebrates in many tissues, and its expression may change in pathological 
conditions  (Vezzalini  et  al.  2007).  RPTPγ  is  present  at  high  levels   in   the  nervous  system,  but   its  
role is currently unknown, although some ligands and a role in mental disorders have been 
proposed (Bouyain and Watking 2010; Hamshere et al. 2009; Zhang et al. 2012). Despite its high 
expression level in the brain, knockout (KO) mice develop normally and present only mild 
behavioral   abnormalities   (Lamprianou   et   al.   2006).   RPTPγ   was   not   normally   found   in   cortical  
astrocytes (Lamprianou et al. 2006), however its transcription can be induced by IL1 and TNFα in 
human astroglioma cell lines in vitro (Schumann et al. 1998).  
Despite being  mainly  a  neuronal  protein,  a  thorough  analysis  of  RPTPγ  distribution  in  the  adult  
brain has been described using a knock-in mice where the promotor of RPTPγ drive LacZ 
expression (Lamprianou et al. 2006). However this analysis did not allow the possibility to 
distinguish  between  the  various  isofoms  of  RPTPγ.  Importantly,  at  least  4  distinct  RPTPγ  isoforms  
exist,   including  a  truncated  soluble  PTP  (sPTPγ),   that   lacks  the  intracellular  catalytic  C-terminal 
domains and it is thus devoid of the phosphatase activity (Shintani et al. 1997). One of the 
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limitations  in  studying  different  RPTPγ  isoforms  is  the  scarceness  of  antibodies  against  different  
specific epitopes, especially toward the extracellular N-terminal region.  
In this study we used different antibodies against C- and N-terminal epitopes, the last ones 
developed in our laboratory, in order to investigate the distribution of the intra- and of the 
extracellular  domains  of  RPTPγ,  with  the  aim  of  evaluating  whether  specific  isoforms  (Sorio  et  al.  
1995; Mafficini et al. 2007; Vezzalini et al. 2007) could be detectable in tissues. Moreover we 
investigated the consequence of neuroinflammation on its expression. 
We   found  RPTPγ   expression   in   the   neuropil   of   cortical   neurons   and   in   cerebellar   Bergmann  
radial glia, whereas a truncated form lacking the C-terminal domain was present in the soma of 
cortical and hippocampal neurons, in Purkinje cells and interneurons of the cerebellar cortex. We 
also found that astrocytes upregulated both the full length and the truncated  RPTPγ  isoform  during  
neuroinflammation.  
Overall  our  study  highlights  a  role  for  RPTPγ  during  astrocyte  activation   in vivo and highlight 
for the first time in situ a differential distribution of the C- and N-terminal portions, suggesting a 
complex post-translational  regulation  of  RPTPγ  in  the  adult  nervous  system.     
 
Materials and Methods 
 
Animals 
Mice were maintained under standard environmental conditions (temperature, humidity, 12 h/12 
h light/dark cycle, with water and food ad libitum) under veterinarian assistance. Animals 
handling and surgery were performed following a protocol which received approval by the Animal 
Care and Use Committee of the University of Verona (CIRSAL), and authorization by the Italian 
Ministry of Health, in strict adherence to the European Communities Council (86/609/EEC) 
directives, minimizing the number of animals used and avoiding their suffering. 
We used adult C57/BL6J mice purchased from Harlan. 5 months old 5XFAD mice were 
purchased from the Jackson Laboratory (Bar Harbor,   Maine).   Adult   RPTPγ   deficient   mice  
(129SveV) were generously given by Dr. S Harroch from the Institut Pasteur of Paris, France.   
 
Immunofluorescence.  
Under deep anesthesia (tribromoethanol, intraperitoneal dose of 0,5 g/kg body weight) mice 
were transcardially perfused with paraformaldehyde 4% in saline buffer. The brain was excised, 
postfixed  and  cryoprotected  before  freezing.  Brain  slices  (35μm  thick)  were  obtained  and  stained  
with antibodies. Some mice were intraperitoneal (ip) injected with 500μg/kg   of   LPS   (Life  
Technologies) and sacrificed 24h post injection. 
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Free floating cryosections were stained with different combinations of antibodies. Sections were 
permeabilized with the following solution: 2% Bovine Serum Albumin and 0,3% Triton X-100 in 
PBS, pH 7.4 for 30 minutes. Then sections were incubated overnight at 4°C with primary 
antibodies followed by the proper secondary Alexa Fluor-conjugated antibodies (1:1000, Life 
Technologies) for 1h at RT. Nuclei were stained with DAPI (Sigma). After mounting with an anti-
fading solution, slices were studied by fluorescence microscopy (DM6000B, Leica Microsystem) 
and confocal microscopy (TCS-SP5, Leica Microsystem).  
 
Antibodies 
The specificity of antibodies against N-terminus domain of Ptprg-RPTPγ:  chicken  anti-RPTPγ  
(ch-RPTPγ  )  and  rabbit  anti-RPTPγ  (rb-RPTPγ-P4) used in this study were previously described in 
detail (Sorio et al. 1995; Mafficini et al. 2007; Vezzalini et al. 2007, Della Peruta et al., 2010 
Cancer Research). We also used anti-RPTPγ  C-terminus domain developed in goat (goat-RPTPγ  
1:20 Santa Cruz) and anti-PTPζ, (mouse IgG1, 1:250, BD Bioscience). The features of anti-RPTPγ  
antibodies, together with the epitope localizations are given in Table 1. 
Neuronal and glial markers used were: anti-MAP2 (mouse IgG1, 1:1000, Sigma-Aldrich), anti-
NeuN (mouse IgG1, 1:200, Chemicon), anti-βIII-tubulin (Rabbit, 1:1000, Sigma-Aldrich), anti-
Amyloid  β  clone  4G8  (IgG2b,  1:200,  Covance),  anti-Calbindin (IgG1, 1:500, Swant), anti-GFAP 
(IgG1, 1:500, Chemicon), anti-S100 (Rabbit, 1:400, Dako) and anti-CD11b (rat, 1:1000, Serotec). 
 
Tissue lysate  
C57 mice were sacrificed by terminal anesthesia 24h after LPS or saline ip injection. After a 
transcardial perfusion with PBS/Heparin in order to discard the blood, brain cortices were quickly 
removed, frozen in liquid nitrogen vapor and stored at -80°C. Brain cortices were cut by cryostat 
and  30  μm  sections  were  homogenized  in  lysis  buffer  (LB)  containing  50  mM  Tris  (pH  7.4), 1% 
Triton X-100, 150 mM NaCl, 200 µM NaVO4, 1 mM EDTA, 1 mM DTT, 1 mM NaF and 
Complete EDTA-free Protease Inhibitor Cocktail Tablets (Roche, Germany), incubated for 20 min 
in a rotating wheel at 4°C and then centrifuged for 15 min at 4 °C at 15000 ×g in a Biofuge Pico 
(DJB Labcare Ltd. UK). All the lysis procedures were carried out at 4°C.  
 
Western Blot 
After protein quantification by Bradford assay, equal amounts of protein were resuspended in 
sample buffer (SB: 40 mM Tris-HCl pH 6.8, 183 mM β-mercaptoethanol, 1% SDS, 5% glycerol) 
and denatured at 95°C for 10 minutes. Lysates were resolved on 7,5 % SDS-PAGE and 
electroblotted onto polyvinylidene difluoride membrane (Millipore Corp., Bedford, MA). The 
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membrane was blocked with 5% BSA in TBS containing 0.05 % Tween-20 (TBST) for anti-
GFAP (1:1000), and 5% skimmed milk for rb-RPTPγ-P4 (1µg/ml) in 1% BSA TBST buffer 
overnight. After washes in TBST, the membrane was incubated with rabbit anti-goat-HRP (Sigma-
Aldrich) or goat anti-mouse-HRP (GE Helthcare, Little Chalfont, UK) for 1 h. After washing with 
TBST, the signal was detected with the enhanced chemiluminescence kit (Millipore Corp., 
Bedford, MA) using an ImageQuant LAS 4000 (GE healthcare) imager. Band intensity was 
detected by Quantity One software (Biorad) and normalized to Ponceau Red staining. 
 
Results 
 
1- RPTPγ  is  a  neuronal  protein  of  widespread  distribution  in  the  adult  mouse  brain. 
 
In   order   to   investigate   the   expression   and   distribution   of   RPTPγ   and   related   isoforms   in   the  
adult mouse brain, we stained brain sections with antibodies against either the extracellular N-
terminal domain or the intracellular C-terminal portion. To detect the extracellular N-terminal 
domain we used antibodies made in chicken and developed in our laboratory (Vezzalini et al. 
2007). Moreover, we used neuronal and glial markers to identify the different cell type. As shown 
in   figure   1,   we   found   that   RPTPγ   was   widely   distributed   throughout   the   brain,   with  
immunopositivity in many neurons of the cerebral cortex and in the hippocampus. Its distribution 
was mainly neuronal, as demonstrated   by   βIII-tubulin colocalization (Fig. 1 a-c). Astrocyte 
positivity was dependent on cell size and on the degree of Glial Fibrillary Acidic Protein (GFAP) 
expression: small astrocytes with thin GFAP-positive  processes  were  negative  to  RPTPγ  (Fig.  1  j-
l), whereas bigger astrocytes, such as those of the hippocampus (Fig. 1 d-f and m) or perivascular 
astrocytes (Fig. 1 g-i), with thick GFAP-positive processes were generally positive to RPTPγ.  
Microglial cells were negative (Fig. 1 n-o). 
In the cerebellum (Fig. 2), RPTPγ  positivity  was  found  in  the  molecular  layer,  in  Purkinje  cells  
(soma and main dendrites but not in spiny branchlets) and interneurons as demonstrated by 
colocalization  with  βIII-tubulin. Colocalization with the radial glial markers S100 and GFAP in 
the   cerebellar   cortex   revealed   a  RPTPγ  positivity   of  Bergmann  glial   cells,   the   radial   glia  of   the  
cerebellum. Almost all deep cerebellar nuclei were also strongly positive (not shown). 
Using the fluorescence microscope we performed an atlas-based analysis of some coronal 
sections  at  different  distances  from  the  bregma,  and  we  found  that  RPTPγ  was  widely  expressed  in  
many   structures   throughout   the   brain.   Results   are   summarized   in   Table   2.   RPTPγ  
immunoreactivity was present in different layers of the cerebral cortex, in the striatum, in many 
nuclei of the thalamus and of the brainstem, and it was generally a neuronal protein in the normal 
 6 
adult mouse brain. Many elements of the white matter were negative, except for some big 
astrocytes. The wide distribution   of   RPTPγ   suggests   that   it  may   have   a   role   in   the   building   or  
maintenance of synaptic circuitry in the brain. 
Differential labeling and confocal analysis of the C- and N-terminal domain epitopes show that 
the two portions of the phosphatase colocalize in the neuropil, but not in the soma of neurons, in 
which the N-terminal epitope positivity was mainly found (Fig. 3). Interestingly, in the cerebellum 
the two portions colocalize in Bergmann glial cells, thus indicating the presence of a full length 
RPTPγ   isoform.   The   N-terminal positivity was found alone in Purkinje cells and cerebellar 
interneurons, indicating the presence of truncated forms.  
These  data  shows  that  distinct  isoforms  of  RPTPγ  are  present  in  different  types  of  neurons/glial  
cells of the brain in physiological conditions. 
We also performed a staining on a few slices of one heterozygous and one RPTPγ KO mouse 
(Lamprianou et al. 2006). Despite some residual staining remained, we observed a strong 
reduction of the RPTPγ positivity as compared to the heterozygous control (see supplementary 
figure). 
 
2- RPTPγ  and  RPTPζ, expressions are distinct 
 
RPTPγ  and  RPTPζ, are members of the same family of tyrosine phosphatases and are highly 
homologous. To assess the specificity of our antibodies against   RPTPγ,   we   stained   sections  
simultaneously  for  RPTPγ  and  RPTPζ, which resulted in a distinct staining pattern. Both proteins 
were neuronal, but RPTPζ was observed as a spotted labeling along the neuropil both in the cortex 
and in the hippocampus (Fig. 4). Indeed the antibody anti- RPTPζ recognizes the intracellular C-
terminal phosphatase  domain  and  therefore  is  able  to  detect  2  out  of  3  RPTPζ  isoforms.  A  strong  
neuronal post-synaptic signal was previously reported by using this antibody together with a lack 
of positivity in cortical and hippocampal astrocytic processes (Hayashi et al. 2005). Thus it is not 
surprising that in our sections hippocampal astrocytes were negative for RPTPζ (Fig. 4 i). In the 
cerebellum RPTPζ was found only in Purkinje cell dendrites, but not in radial glia (Fig. 4 j-l). Our 
data show that the staining for RPTPζ,   and  RPTPγ   in   neurons  were   distinct   and   only   partially  
overlapping, thus supporting the specificity  of  our  antibodies  against  RPTPγ  and  suggesting  that  
the two proteins can be expected to have different and specific functions in neurons, even if they 
are highly homologous. 
 
3- RPTPγ  distribution  in  inflammatory  states:  LPS  and  AD 
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The expression of RPTPγ in protoplasmic astrocytes with thick GFAP-positive branches under 
physiological conditions prompted us to investigate whether its expression could increase in brain 
during inflammation. Thus, we performed the staining of brain sections in mice sacrificed 24 h 
after LPS ip injection, a treatment that is known to cause a general brain inflammation and glial 
cell activation within 24 h from injection (Kwon et al. 2010). We found that activated GFAP-
positive cortical astrocytes were strongly positive for RPTPγ,   while   the   protein   distribution   in  
neurons did not change significantly (Fig. 5 a to d). In order to quantify this phenomenon, we 
performed western blotting experiments on cerebral cortices of adult mice with or without LPS 
injections. As shown in Fig. 5 e, the increase of GFAP reflects the increase of activation state of 
astrocytes 24h after LPS treatment. We also performed western blotting using an anti-RPTPγ  
antibody made in rabbit (Rb-RPTPγ-P4) (Sorio et al. 1995), that revealed an increase, upon LPS 
treatment,  of  all  the  3  isoforms  detected:  the  full  length  RPTPγ  (180kDa  band)  and  two  truncated  
isoforms at 120 and 80kDa bearing the extracellular N-terminal portion that is recognized by the 
above mentioned antibody (Fig. 5 e). Interestingly, the densitometry revealed that after LPS the 
120 kDa band, increased much more than the others (180 kDa) (p<0,01 by t-test). Moreover the 
normalized expression level of the isoforms remained linearly correlated among the 3 individual 
mice, with a r2 from of 0.67 to 0.77 (Fig 5 g to i), suggesting that the smaller isoforms might 
derive from proteolytic cleavage of the longers. As gel loading control the Ponceau staining is also 
shown. 
We further confirmed that activated astrocytes express  high  levels  of  RPTPγ  in  another  model  
of   brain   inflammation:   the   5XFAD   mouse,   one   of   the   murine   models   of   Alzheimer’s   disease  
(Oakley et al. 2006). We stained cerebral sections of a 6 months old mouse in order to detect 
amyloid plaques in the cerebral cortex  by  using  the  4G8  antibody.  This  antibody  labels  amyloid  β  
and its precursors such as the neuronal Amyloid Precursor Protein (APP), which are ubiquitously 
expressed in neurons. For this reason many neurons are positive for 4G8 staining (Fig. 6). In tissue 
sections the amyloid plaques are clearly recognizable by their morphology. The strong activation 
of astrocytes and microglia around the amyloid plaques is visualized by the cell morphology 
(astrocytes here are bigger and present thick processes) and the elevation of the specific markers 
GFAP and Cd11b. Also, in this model of neuroinflammation, neurons and astrocytes were 
strongly  positive  for  RPTPγ.  On  the  contrary,  both  activated  microglial  cells  and  amyloid  plaques  
were negative. 
All  together  these  data  suggest  that  RPTPγ  is  generally  upregulated  during  neuroinflammation  
in vivo and might play a role in astrocyte activation. 
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Discussion 
 
In   this   study   we   investigated   the   distribution   of   RPTPγ   and   related   isoforms   in   the   nervous  
system by using, for the first time in the literature, simultaneously antibodies against C- and N-
terminus epitopes of the protein. These antibodies are able to distinguish between the full length 
(colocalization of C- and N- terminus) and the truncated isoforms lacking C-terminus domain 
(only N-terminus positivity) of the phosphatase. In line with previous studies (Lamprianou et al. 
2006),  we  found  a  predominant  and  widespread  neuronal  RPTPγ  immunopositivity  throughout  the  
brain. Using the C- and N-terminus antibodies, we further analyzed the  expression  of  RPTPγ:  both  
N- and C-terminus were found in the neuropil of cortical and hippocampal neurons demonstrating 
a  RPTPγ  full   length  expression. The positivity for the N-terminal domain was found also in the 
soma, often without its C-terminal counterpart showing an expression of a shorter isoform in the 
soma. Thus, at least two  isoforms  of  RPTPγ  are  present  in  the  adult  normal  murine  brain  and  are  
differentially distributed not only in different types of neurons, but also in different compartments 
of the same cell. Clarifying whether the truncated N-terminal isoforms are produced by alternative 
splicing or by proteolytic cleavage starting from the full-length protein, will be object of further 
studies. Indeed a proteolytic cleavage in vivo have been already hypothesized, but not yet 
demonstrated, studying   the   changes   in   RPTPγ   expression during mouse development in the 
superior colliculus: here three different isoforms were detected at different time points from E13 to 
P20 (Reinhard et al. 2009). 
It   was   reported   that   RPTPγ  KO  mice   did   not   show   any   obvious   phenotype,   displaying   only 
minor behavioral changes, in spite of the expression during development and in the adult brain in 
pyramidal   and   sensory   neurons   (Lamprianou   et   al.   2006;;   Zhang   et   al.,   2012).   Indeed  RPTPγ   is  
highly homologous to RPTPζ, and both are expressed in neurons (Shintani et al. 1998; Tanaka et 
al. 2003; Hayashi et al. 2005), suggesting that potentially they might have overlapping activities at 
the occurrence and RPTPζ,   could   compensate   the   loss   of   RPTPγ.   We   stained   our   sections  
simultaneously  for  RPTPγ  and  for  RPTPζ, and found only partial overlapping signals in neurons 
and, an overall different staining pattern. Beside supporting the specificity of the antibodies 
against the N-terminal  portion  of  RPTPγ  these  results  suggest  that  PTPs  other  than  RPTPζ might 
compensate for RPTPγ loss during the embryonal development of KO mice.  
This   report   supports   the   previous   studies   on   the   pattern   of   expression   of   RPTPγ   and   RPTPζ. 
Despite it is reported that RPTPζ is strongly expressed in glial cells (oligodendrocytes and 
astrocytes) we found a spotted-like positivity in cortical and hippocampal neurons, in line with 
previous studies that used the same antibodies (Hayashi et al. 2005), while   RPTPγ   had   a   very  
strong expression in neurons (Lamprianou et al, 2006). We show that most perivascular astrocytes 
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do  not  express  RPTPγ in normal adult mouse brain, and that in some sublocalisation of neurons 
both RPTPζ and  RPTPγ  can  be  detected. 
The  RPTPγ  role  and  function  in  the  adult  CNS  is unknown and largely unexplored, as well as 
are  its  ligands.  RPTPγ  could  putatively  bind to contactins-3, -4 and -5 that are widely distributed 
in the adult brain, but the meaning of this interaction is unclear (Bouyain and Watkins 2010; 
Lamprianou et al. 2011; Hendriks et al. 2013).  Some  recent  data  support  a  function  of  RPTPγ  in  
depression (Zhang et al. 2012) and bipolar disorders (Hamshere et al. 2009). This is in line with its 
potential interaction with the CNTNs and CNTNs signaling pathway, which are genes mutated in 
mental disorders (Cottrel et al. 2011). 
In   chick   spinal   cord   RPTPγ   plays   a   role   in   spinal   cord   neurogenesis   during   embryonic  
development,   where   it   appears   to   influence   the  Wnt/β   catenin   signaling   and   neuronal   survival  
(Hashemi et al. 2011). Moreover  RPTPγ   inhibits   the  NGF-mediated neurite outgrowth in PC12 
cells  (Shintani  et  al.  2001).  Our  study  is  the  first  that  describes  the  distribution  of  different  RPTPγ  
isoforms in the brain, and it completes and enriches the current knowledge about the distribution 
of  RPTPγ  and  could  help  in  developing  new  hypotheses  about  its  role  and  molecular  mechanisms  
in neurons of the adult brain.  
Another major finding of our study is that, despite not being expressed in small astrocytes, 
RPTPγ   is  up-regulated in these same cells following intraperitoneal injection of LPS and in the 
5XFAD  murine  model   of   Alzheimer’s   disease,   two  well   characterized   in vivo models of brain 
inflammation. These data suggest, for the first time in vivo,   that  RPTPγ  can   be   involved   in   the 
process  of  astrocyte  activation.  It  is  already  known  that,  after  Interleukin  1  β  (IL1  β)  and  Tumor  
Necrosis   Factor   alpha   (TNFα)   treatment   in vitro,   RPTPγ   mRNA   is   upregulated   by   human  
astrocytoma cells (Schumann et al. 1998). Indeed after LPS ip treatment both   IL1  β   and  TNFα  
mRNA are upregulated in mouse brain within 90min, and the astrocyte activation reaches its 
maximum at 24h post injection (Kwon et al. 2010). In this study we showed that 24h after LPS 
injection the increase in GFAP level is accompanied by   the   increase   in  RPTPγ  protein   level   in  
brain astrocytes. This is the first time that this increase is demonstrated in vivo on different 
isoforms   of   RPTPγ.   Indeed,   we   observed   a   marked   increase   of   the   120   kDa   truncated   RPTPγ  
isoform by WB after LPS treatment. Since all isoforms present a reciprocal linear correlation, it 
might be possible that the truncated isoforms are produced in part by cleavage starting from the 
longer ones. Interestingly following LPS treatment, activated microglia and astrocytes are known 
to produce many different matrix metalloproteases like MMP-3 and MMP-9 (Gottschall and Deb 
1996; Lee et al. 2003). Cytokines  like  IL1  β  and  TNFα  are  potent  stimulant  of  MMPs  production  
by activated glia in vitro (Gottschall and Yu 1995; Crocker et al. 2006; for a review see 
Candelario-Jalil et al. 2009). The possible role of matrix metalloproteases in the cleavage of 
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RPTPγ  during  neuroinflammation  will  be  object  of  further  studies.  Indeed  we  cannot  exclude  that  
short and long isoforms are produced by alternative spicing, as happens for RPTP, that is highly 
homologous  to  RPTPγ. 
As concern the RPTP signal, we found a punctuate staining pattern in neurons, in line with 
previous studies where this protein was found to be localized post-synaptically and not in 
astrocytes when the same antibody was used (Hayashi et al. 2005; Kawachi et al. 1999). It has 
been reported for long time that RPTP is expressed in astrocytes (Canoll et al. 1996; Sakurai et 
al.1996;). Among the three splicing variants, its soluble isoform phosphacan lacking the 
intracellular domain is released during inflammation or lesion (Faissner et al. 2006). A possible 
explanation for this lack of positivity in astrocytes might be that mature astrocytes preferentially 
express the phosphacan isoform (Canoll 1996 et al.; Sakurai 1996 et al.), which is not detected by 
this antibody. 
More recent studies suggest that the neuronal RPTP isoforms might play a critical role in the 
reactive synaptogenesis occurring after injury (Harris et al., 2011). Indeed the last decade of 
research on Phosphacan/RPTP isoforms reveals a high degree of complexity in the regulation and 
roles of this particular phosphatase in both physiological and pathological conditions (Lamprianou 
et al. 2011; Hendriks et al. 2013). 
In   this  study,  we  show  an   increased  expression  of   the  RPTPγ isoform lacking the D2 domain 
upon   inflammation.   RPTPγ   inhibits  NGF signaling and therefore TRK dependent axon growth 
(Shintani 2001). Using different signaling pathways, RPTP and  RPTPγ   could   generate   similar  
biological function such as modulating neurite outgrowth during inflammation. The increased 
expression of the RPTPγ  isoform  lacking  a  C-terminal portion, likely including the D2 domain, is 
of interest. Indeed structural biology of PTPs proposed that these proteins homodimerize inducing 
inhibition of the phosphatase activity by changing the relative position of the D1 and D2 domains 
(Tremblay 2009; Barr et al. 2009). Thus, an isoform lacking the D2 domain could not be inhibited 
by this mechanism and could strengthen its efficacy to dephosphorylate the NGF/TRK signaling 
or other still unidentified pathways.  
In this line   both   phosphatase   RPTPγ   and   RPTP should increase in astrocytes when 
inflammation occurs. Indeed, as one of the main components of Condroitin Sulfate Proteoglycans 
(CSPGs), phosphacan is expressed at high level by reactive astrocytes upon injury, and prevent 
axon growth by direct binding to the surface of the growth cone and by interacting with 
L1/NgCAM/laminin   substrates   (for  a   review  see  Sandvig  et   al.,  2004).  RPTPγ   is  also  expressed  
upon cytokines treatment and inflammation. If both phosphatases have only partial overlap of 
expression, they might address similar biological function. 
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Overall,   our   study   enriches   the   current   knowledge   about   the   role   of   RPTPγ   in   astrocyte  
activation in vivo and   the  differential  distribution  of  RPTPγ   isoforms  could  help   in making new 
hypothesis about the mechanism of action/role of the phosphatase in neuronal physiological 
functions.  
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Figure Legends 
 
Fig.  1  RPTPγ  is  expressed  in  neurons  and  in  some astrocytes in the adult brain. 
Examples   of   immunostaining   showing   the   RPTPγ   positivity   of   neurons   (a-c), astrocytes and 
microglia (d-o).   Colocalization   of   RPTPγ   (green)   and   βIII-tubulin (blue) shows the neuronal 
expression  of  RPTPγ  in  the  cerebral  cortex (a-c). Astrocytes are labeled by GFAP (red). In a and c 
astrocytes surrounding a blood vessel are also shown (red). 
A  representative  image  of  the  dentate  gyrus  shows  the  mild  colocalization  of  RPTPγ  and  GFAP,  
indicating the positivity of some astrocytes in the hippocampus (d-f) as well as those surrounding 
some blood vessels (g-i). Small astrocytes (j-l)  are  negative  for  RPTPγ,  whereas  a  mild  positivity  
was found only in some big astrocytes (GFAP red in m) but not in the resting microglia labeled by 
CD11b (red in n and o). In some images the nuclear DAPI staining is also shown. Scale bars 50μm 
in a to f, 20μm in g to o.  
 
Fig.  2  RPTPγ  is  expressed  in  neurons  of  the  cerebellar  molecular  layer  and  in  cerebellar  
radial glia. 
Immunostaining  showing   the  RPTPγ expression in the cerebellar cortex of adult mouse brain. 
(a-d)  Colocalization  of  RPTPγ  (green)  and  βIII-tubulin (red) shows positivity for interneurons of 
the molecular layer, as well as Purkinje cell main dendrite. e-h.   Colocalization   of   RPTPγ   and  
GFAP (red) shows positivity for Bergmann radial glia. g and h are enlargements of the boxed 
region in f. (i-l)   Colocalization   of   RPTPγ   and   the   Bergmann   glia   specific   marker   S100   (red)  
confirms  the  expression  of  RPTPγ  in  these  cells.  k  is  an  enlargement  of  the  boxed region in j. In 
some images nuclei counterstaining by DAPI (blue) is also shown. ML: molecular layer; PL: 
Purkinje cell layer; GCL: granule cell layer. Scale bars 20μm in g, h, k, l, 40μm in all the other 
images. 
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Fig.  3  RPTPγ  C- and N-terminal epitopes are differently localized within brain cells. 
Immunostaining of brain sections by using different antibodies against either the N- (anti-
RPTPγ   chicken   isotype,   green)   or   the   C-terminal   (red)   portion   of   RPTPγ   allows   to   distinguish  
between the full length protein (colocalization) and a truncated isoform lacking the C-terminus 
epitope (green only). (a-b) cerebral cortex shows that the N- and C-terminus colocalizes in the 
apical dendrite and in some neurons, but the soma mainly presents the N-terminus positivity alone. 
(c-d) enlargements of the boxed region in a. (e-h) shows that resting astrocytes (GFAP, blue) are 
negative for both epitopes. (i-l) Cerebellar cortex displays C- and N- terminus colocalization only 
in Bergamnn radial glia, whereas the N-terminal epitope is present alone in Purkinje cells and 
colocalizes with Calbindin (blue). ML: molecular layer; PL: Purkinje cell layer. Scale bars 30μm 
in a, b, i, j, k, l; 15μm in c, d, e, f, g, h.  
 
Fig. 4 Comparison of the distribution of RPTPζ and  RPTPγ  receptors. 
Immunostaining of brain sections by using anti-RPTPγ   (antibody  made   in   chicken)   and   anti-
PTPζ, a protein that is highly homologous with RPTPγ.  a-f Cerebral cortex, where colocalization 
of  RPTPγ  (green)  and  RPTPζ,  (red)  occurs  in  the  neuropil  (βIII-tubulin, blue). f is an enlargement 
of the boxed region in d and shows the spotted staining pattern of RPTPζ. g-i In the hippocampus 
both proteins are neuronal. The boxed region enlarged in i shows astrocytes that are negative for 
PTPζ (arrows). j-l In the cerebellar cortex RPTPζ was found in Purkinje cell primary dendrites 
where  it  partially  colocalizes    with  RPTPγ. 
The different localizations and staining patterns of RPTPζ,   and   RPTPγ   further   support   the  
specificity of our N-terminal  antibodies  against  RPTPγ N-terminal domain. ML: molecular layer; 
PL: Purkinje cell layer. Scale bars 30μm. 
 
Fig.  5  RPTPγ  expression  increases  in  astrocytes  after  LPS  injection. 
RPTPγ   expression   in   mouse   brain   cortex   24h   after   LPS   i.p.   injection   was   assessed   by  
immunostaining and WB. (a-d)  Immunostaining  showing  a  strong  positivity  for  RPTPγ  (green)  in    
activated astrocytes (GFAP, red; colocalization yellow). The boxed region of a is enlarged in b, c 
and d, in order to highlight activated astrocytes surrounding a blood vessel. Scale bars 30μm. (e) 
WB of brain cortex lysates of 3 normal (-)  and  3  LPS  (+)  treated  mice.    Band  intensity  of  RPTPγ  
was detected by an antibody made in rabbit (rb-RPTPγ-P4). Bands at 180kDa show the full length 
protein isoform, whereas at 120 and 80 kDa we found two truncated isoforms. GFAP increase 
confirms the astrocyte activation after LPS injection. Ponceau staining was used for normalization 
of the loaded protein. The densitometry plot (f) shows the normalized band intensity relative to  
120 and 180kDa isoforms with or without LPS treatment. All isoforms increased after LPS 
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treatment,  especially  the  truncated  120kDa  RPTPγ.  p<0,01  by  t-test. (g-i) Plots showing the strong 
linear   correlation   between   the   normalized   intensities   of   the   3   RPTPγ   isoforms   showed   in e, 
suggesting their origin from a common precursor. 
 
Fig.   6   RPTPγ   is   expressed   in   cortical   activated   astrocytes   in   the   murine   model   of  
Alzheimer’s  disease. 
Expression  of  RPTPγ  (green)  was  assessed  in  brain  cortex  of  a  6  month  old  5xFAD  mouse  brain  
by immunostaining.  Staining  for  amyloid  β  peptide  (4G8,  red)  shows  neuronal  APP  and  amyloid  
plaques (red). (a-b)  RPTPγ  (green)  is  neuronal,  but  a  strong  positivity  was  found  also  in  astrocytes  
(GFAP, blue in a, red in b, false color). (c) shows the colocalization  of  RPTPγ  (green)  and  4G8  
(red) in neurons but not in amyloid plaques. (d-f) Activated microglia (CD11b, red) surrounding 
amyloid  plaques  is  negative  for  RPTPγ.  (f)  represents  an  enlargement  of  the  boxed  region  in  d.  (g-
i)  Neuronal  expression  of  RPTPγ   in  AD mice assessed by colocalization with MAP2 (blue in g 
and red in h, false color). Scale bars 40 μm in a-e, 20 μm in f-i.    
 
Supplementary figure  
As an additional test for antibody specificity we stained some slides from one heterozygous and 
one   RPTPγ  KO mouse using the two antibodies against the N- (ch-RPTP, green) and the C-
terminus (goat-RPTP, red) epitopes of the phosphatase. Cerebral cortex (A-F and J-O) and 
hippocampus (G-I and P-R) showed a strong decrease of RPTP signal in the KO (J to R) in 
comparison to the heterozygous (A to I). A residual staining was still present in some regions, in 
particular in the granular layer of the hippocampus, a region known to be prone to aspecific 
staining. Scale bars 50m. 
 
Table 1  
Schematic representation of the  antibodies  used  against  RPTPγ.  Epitopes:  amino  acid  number  of  
epitopes, validated application: IP= immuno-precipitation, WB= western blot, IHC= immuno histo 
chemistry,   Flow=   flow   cytometry,   IF=   immuno   fluorescence.   The   RPTPγ   structure   scheme    
displays where the epitopes are localized within the predicted protein sequence of the 4 different 
isoforms. CA: Carbonic anhydrase-like; FNIII: Fibronectin type III-like domain; TM: 
transmembrane portion; D1: active phosphatase domain and D2: inactive phosphatase domain.  
 
 Table 2 
Distribution  of  RPTPγ  positivity  in  mouse  brain  coronal  sections,  assessed  by  immunostaining  
and fluorescence microscopy.  
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Abstract 
The   receptor   protein   tyrosine   phosphatase   γ   (Ptprg-RPTPγ)   is   a receptor protein widely 
expressed  in  many  tissues,  including  the  central  nervous  system  (CNS).  Several  RPTPγ  isoforms  
are expressed in the brain during development and in adulthood, but their distribution and role are 
unknown. In this study we investigated the distribution  of  some  RPTPγ  isoforms  in  the  adult  brain  
by using antibodies against the epitopes localized in the C- and in the N-terminal domains of the 
full length   isoform   of   RPTPγ.   We   found   a   predominant   and   widespread   neuronal   positivity  
throughout the neocortex, hippocampus, striatum and in many nuclei of the brainstem and 
cerebellum. At least 2 distinct isoforms that can co-exist in various compartments in the same cell 
are detectable in different neuron types. Immunopositivity for epitopes located in both the N- and 
C-terminus domains were found in the neuropil of cortical and hippocampal neurons, whereas the 
N-terminal domain positivity was found in the soma, often without colocalization with its C-
terminal counterpart. Among glial cells, some protoplasmic and perivascular astrocytes and the 
cerebellar   Bergmann   glia,   express   RPTPγ.   The   astrocytic   expression   of   RPTPγ   and   putative  
processing isoforms of 120 and 80 kDa increases during neuroinflammation, in particular 24h after 
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LPS treatment. Activated astrocytes were  found  to  be  strongly  positive  for  RPTPγ  also  in  a  mice  
model   of   Alzheimer’s   disease.   Our   results   confirm   previous   findings   and   enrich   the   current  
knowledge   of   RPTPγ   distribution   in   the   CNS,   highlighting   a   role   of   RPTPγ   during  
neuroinflammation processes. 
Key words (4-6):  RPTPγ,  neuroinflammation,  LPS,  RPTPζ,  reactive  astrocytes  and  Alzheimer’s  
disease. 
 
Introduction 
 
It is now well established that in the brain receptor-subtype protein kinases and phosphatases are 
key regulators of signaling mechanisms underlying synaptic network orchestration (Dabrowski 
and Umemori 2011) and neuron-glia interactions (Faissner et al. 2006). While protein tyrosine 
kinases have been extensively studied so far, the role and the functions of receptor protein tyrosine 
phosphatases (RPTPs) are less known (for a review see Tonks 2006). RPTPs are classified into 
distinct groups, on the basis of their structure (Johnson and Van Vactor 2003). The Receptor 
Protein   Tyrosine   Phosphatase   γ   (RPTPγ)   is   a   member   of   the   V   subgroup   of   Receptor   PTPs  
together with its highly homologous PTP zeta (RPTPζ) (Barnea et al. 1993; Nishiwaki et al. 1998). 
The structure of these proteins includes a carbonic anhydrase-like domain and a fibronectin 
domain that together with a spacer region form the extracellular N-terminal portion. The 
intracellular C-terminal portion presents 2 tyrosine phosphatase domains, one of which lacks the 
catalytic activity (Barnea et al. 1993; Lamprianou and   Harroch   2006).   RPTPγ   is   expressed   in  
developing and adult vertebrates in many tissues, and its expression may change in pathological 
conditions  (Vezzalini  et  al.  2007).  RPTPγ  is  present  at  high  levels   in   the  nervous  system,  but   its  
role is currently unknown, although some ligands and a role in mental disorders have been 
proposed (Bouyain and Watking 2010; Hamshere et al. 2009; Zhang et al. 2012). Despite its high 
expression level in the brain, knockout (KO) mice develop normally and present only mild 
behavioral   abnormalities   (Lamprianou   et   al.   2006).   RPTPγ  was not normally found in cortical 
astrocytes (Lamprianou et al. 2006), however its transcription can be induced by IL1 and TNFα in 
human astroglioma cell lines in vitro (Schumann et al. 1998).  
Despite being  mainly  a  neuronal  protein,  a  thorough  analysis  of  RPTPγ  distribution  in  the  adult  
brain has been described using a knock-in mice where the promotor of RPTPγ drive LacZ 
expression (Lamprianou et al. 2006). However this analysis did not allow the possibility to 
distinguish  between  the  various  isofoms  of  RPTPγ.  Importantly,  at  least  4  distinct  RPTPγ  isoforms  
exist,   including  a  truncated  soluble  PTP  (sPTPγ),   that   lacks  the  intracellular  catalytic  C-terminal 
domains and it is thus devoid of the phosphatase activity (Shintani et al. 1997). One of the 
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limitations  in  studying  different  RPTPγ  isoforms  is  the  scarceness  of  antibodies  against  different  
specific epitopes, especially toward the extracellular N-terminal region.  
In this study we used different antibodies against C- and N-terminal epitopes, the last ones 
developed in our laboratory, in order to investigate the distribution of the intra- and of the 
extracellular  domains  of  RPTPγ,  with the aim of evaluating whether specific isoforms (Sorio et al. 
1995; Mafficini et al. 2007; Vezzalini et al. 2007) could be detectable in tissues. Moreover we 
investigated the consequence of neuroinflammation on its expression. 
We   found  RPTPγ   expression   in   the   neuropil   of   cortical   neurons   and   in   cerebellar   Bergmann  
radial glia, whereas a truncated form lacking the C-terminal domain was present in the soma of 
cortical and hippocampal neurons, in Purkinje cells and interneurons of the cerebellar cortex. We 
also found that astrocytes upregulated both the full length and the truncated  RPTPγ  isoform  during  
neuroinflammation.  
Overall  our  study  highlights  a  role  for  RPTPγ  during  astrocyte  activation   in vivo and highlight 
for the first time in situ a differential distribution of the C- and N-terminal portions, suggesting a 
complex post-translational  regulation  of  RPTPγ  in  the  adult  nervous  system.     
 
Materials and Methods 
 
Animals 
Mice were maintained under standard environmental conditions (temperature, humidity, 12 h/12 
h light/dark cycle, with water and food ad libitum) under veterinarian assistance. Animals 
handling and surgery were performed following a protocol which received approval by the Animal 
Care and Use Committee of the University of Verona (CIRSAL), and authorization by the Italian 
Ministry of Health, in strict adherence to the European Communities Council (86/609/EEC) 
directives, minimizing the number of animals used and avoiding their suffering. 
We used adult C57/BL6J mice purchased from Harlan. 5 months old 5XFAD mice were 
purchased from the Jackson Laboratory (Bar Harbor, Maine). Adult   RPTPγ   deficient   mice  
(129SveV) were generously given by Dr. S Harroch from the Institut Pasteur of Paris, France.   
 
Immunofluorescence.  
Under deep anesthesia (tribromoethanol, intraperitoneal dose of 0,5 g/kg body weight) mice 
were transcardially perfused with paraformaldehyde 4% in saline buffer. The brain was excised, 
postfixed  and  cryoprotected  before  freezing.  Brain  slices  (35μm  thick)  were  obtained  and  stained  
with antibodies. Some mice were intraperitoneal (ip) injected with 500μg/kg   of   LPS   (Life  
Technologies) and sacrificed 24h post injection. 
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Free floating cryosections were stained with different combinations of antibodies. Sections were 
permeabilized with the following solution: 2% Bovine Serum Albumin and 0,3% Triton X-100 in 
PBS, pH 7.4 for 30 minutes. Then sections were incubated overnight at 4°C with primary 
antibodies followed by the proper secondary Alexa Fluor-conjugated antibodies (1:1000, Life 
Technologies) for 1h at RT. Nuclei were stained with DAPI (Sigma). After mounting with an anti-
fading solution, slices were studied by fluorescence microscopy (DM6000B, Leica Microsystem) 
and confocal microscopy (TCS-SP5, Leica Microsystem).  
 
Antibodies 
The specificity of antibodies against N-terminus domain of Ptprg-RPTPγ:  chicken  anti-RPTPγ  
(ch-RPTPγ  )  and  rabbit  anti-RPTPγ  (rb-RPTPγ-P4) used in this study were previously described in 
detail (Sorio et al. 1995; Mafficini et al. 2007; Vezzalini et al. 2007, Della Peruta et al., 2010 
Cancer Research). We also used anti-RPTPγ  C-terminus domain developed in goat (goat-RPTPγ  
1:20 Santa Cruz) and anti-PTPζ, (mouse IgG1, 1:250, BD Bioscience). The features of anti-RPTPγ  
antibodies, together with the epitope localizations are given in Table 1. 
Neuronal and glial markers used were: anti-MAP2 (mouse IgG1, 1:1000, Sigma-Aldrich), anti-
NeuN (mouse IgG1, 1:200, Chemicon), anti-βIII-tubulin (Rabbit, 1:1000, Sigma-Aldrich), anti-
Amyloid  β  clone  4G8  (IgG2b,  1:200,  Covance),  anti-Calbindin (IgG1, 1:500, Swant), anti-GFAP 
(IgG1, 1:500, Chemicon), anti-S100 (Rabbit, 1:400, Dako) and anti-CD11b (rat, 1:1000, Serotec). 
 
Tissue lysate  
C57 mice were sacrificed by terminal anesthesia 24h after LPS or saline ip injection. After a 
transcardial perfusion with PBS/Heparin in order to discard the blood, brain cortices were quickly 
removed, frozen in liquid nitrogen vapor and stored at -80°C. Brain cortices were cut by cryostat 
and  30  μm  sections  were  homogenized  in  lysis  buffer  (LB)  containing  50  mM  Tris  (pH  7.4), 1% 
Triton X-100, 150 mM NaCl, 200 µM NaVO4, 1 mM EDTA, 1 mM DTT, 1 mM NaF and 
Complete EDTA-free Protease Inhibitor Cocktail Tablets (Roche, Germany), incubated for 20 min 
in a rotating wheel at 4°C and then centrifuged for 15 min at 4 °C at 15000 ×g in a Biofuge Pico 
(DJB Labcare Ltd. UK). All the lysis procedures were carried out at 4°C.  
 
Western Blot 
After protein quantification by Bradford assay, equal amounts of protein were resuspended in 
sample buffer (SB: 40 mM Tris-HCl pH 6.8, 183 mM β-mercaptoethanol, 1% SDS, 5% glycerol) 
and denatured at 95°C for 10 minutes. Lysates were resolved on 7,5 % SDS-PAGE and 
electroblotted onto polyvinylidene difluoride membrane (Millipore Corp., Bedford, MA). The 
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membrane was blocked with 5% BSA in TBS containing 0.05 % Tween-20 (TBST) for anti-
GFAP (1:1000), and 5% skimmed milk for rb-RPTPγ-P4 (1µg/ml) in 1% BSA TBST buffer 
overnight. After washes in TBST, the membrane was incubated with rabbit anti-goat-HRP (Sigma-
Aldrich) or goat anti-mouse-HRP (GE Helthcare, Little Chalfont, UK) for 1 h. After washing with 
TBST, the signal was detected with the enhanced chemiluminescence kit (Millipore Corp., 
Bedford, MA) using an ImageQuant LAS 4000 (GE healthcare) imager. Band intensity was 
detected by Quantity One software (Biorad) and normalized to Ponceau Red staining. 
 
Results 
 
1- RPTPγ  is  a  neuronal  protein  of  widespread  distribution  in  the  adult  mouse  brain. 
 
In   order   to   investigate   the   expression   and   distribution   of   RPTPγ   and   related   isoforms   in   the  
adult mouse brain, we stained brain sections with antibodies against either the extracellular N-
terminal domain or the intracellular C-terminal portion. To detect the extracellular N-terminal 
domain we used antibodies made in chicken and developed in our laboratory (Vezzalini et al. 
2007). Moreover, we used neuronal and glial markers to identify the different cell type. As shown 
in   figure   1,   we   found   that   RPTPγ   was   widely   distributed   throughout   the   brain,   with  
immunopositivity in many neurons of the cerebral cortex and in the hippocampus. Its distribution 
was mainly neuronal, as demonstrated   by   βIII-tubulin colocalization (Fig. 1 a-c). Astrocyte 
positivity was dependent on cell size and on the degree of Glial Fibrillary Acidic Protein (GFAP) 
expression: small astrocytes with thin GFAP-positive  processes  were  negative  to  RPTPγ  (Fig.  1  j-
l), whereas bigger astrocytes, such as those of the hippocampus (Fig. 1 d-f and m) or perivascular 
astrocytes (Fig. 1 g-i), with thick GFAP-positive processes were generally positive to RPTPγ.  
Microglial cells were negative (Fig. 1 n-o). 
In the cerebellum (Fig. 2), RPTPγ  positivity  was  found  in  the  molecular  layer,  in  Purkinje  cells  
(soma and main dendrites but not in spiny branchlets) and interneurons as demonstrated by 
colocalization  with  βIII-tubulin. Colocalization with the radial glial markers S100 and GFAP in 
the   cerebellar   cortex   revealed   a  RPTPγ  positivity   of  Bergmann  glial   cells,   the   radial   glia  of   the  
cerebellum. Almost all deep cerebellar nuclei were also strongly positive (not shown). 
Using the fluorescence microscope we performed an atlas-based analysis of some coronal 
sections  at  different  distances  from  the  bregma,  and  we  found  that  RPTPγ  was  widely  expressed  in  
many structures throughout the brain. Results are summarized in Table 2.   RPTPγ  
immunoreactivity was present in different layers of the cerebral cortex, in the striatum, in many 
nuclei of the thalamus and of the brainstem, and it was generally a neuronal protein in the normal 
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adult mouse brain. Many elements of the white matter were negative, except for some big 
astrocytes. The wide distribution   of   RPTPγ   suggests   that   it  may   have   a   role   in   the   building   or  
maintenance of synaptic circuitry in the brain. 
Differential labeling and confocal analysis of the C- and N-terminal domain epitopes show that 
the two portions of the phosphatase colocalize in the neuropil, but not in the soma of neurons, in 
which the N-terminal epitope positivity was mainly found (Fig. 3). Interestingly, in the cerebellum 
the two portions colocalize in Bergmann glial cells, thus indicating the presence of a full length 
RPTPγ   isoform.   The   N-terminal positivity was found alone in Purkinje cells and cerebellar 
interneurons, indicating the presence of truncated forms.  
These  data  shows  that  distinct  isoforms  of  RPTPγ  are  present  in  different  types  of  neurons/glial  
cells of the brain in physiological conditions. 
We also performed a staining on a few slices of one heterozygous and one RPTPγ KO mouse 
(Lamprianou et al. 2006). Despite some residual staining remained, we observed a strong 
reduction of the RPTPγ positivity as compared to the heterozygous control (see supplementary 
figure). 
 
2- RPTPγ  and  RPTPζ, expressions are distinct 
 
RPTPγ  and  RPTPζ, are members of the same family of tyrosine phosphatases and are highly 
homologous. To assess the specificity of our antibodies against   RPTPγ,   we   stained   sections  
simultaneously  for  RPTPγ  and  RPTPζ, which resulted in a distinct staining pattern. Both proteins 
were neuronal, but RPTPζ was observed as a spotted labeling along the neuropil both in the cortex 
and in the hippocampus (Fig. 4). Indeed the antibody anti- RPTPζ recognizes the intracellular C-
terminal phosphatase domain and therefore is able to detect 2 out of 3 RPTPζ isoforms. A strong 
neuronal post-synaptic signal was previously reported by using this antibody together with a lack 
of positivity in cortical and hippocampal astrocytic processes (Hayashi et al. 2005). Thus it is not 
surprising that in our sections hippocampal astrocytes were negative for RPTPζ (Fig. 4 i). In the 
cerebellum RPTPζ was found only in Purkinje cell dendrites, but not in radial glia (Fig. 4 j-l). Our 
data show that the staining for RPTPζ,   and  RPTPγ   in   neurons  were   distinct   and   only   partially  
overlapping, thus supporting the specificity  of  our  antibodies  against  RPTPγ  and  suggesting  that  
the two proteins can be expected to have different and specific functions in neurons, even if they 
are highly homologous. 
 
3- RPTPγ  distribution  in  inflammatory  states:  LPS  and  AD 
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The expression of RPTPγ in protoplasmic astrocytes with thick GFAP-positive branches under 
physiological conditions prompted us to investigate whether its expression could increase in brain 
during inflammation. Thus, we performed the staining of brain sections in mice sacrificed 24 h 
after LPS ip injection, a treatment that is known to cause a general brain inflammation and glial 
cell activation within 24 h from injection (Kwon et al. 2010). We found that activated GFAP-
positive cortical astrocytes were strongly positive for RPTPγ,   while   the   protein   distribution   in  
neurons did not change significantly (Fig. 5 a to d). In order to quantify this phenomenon, we 
performed western blotting experiments on cerebral cortices of adult mice with or without LPS 
injections. As shown in Fig. 5 e, the increase of GFAP reflects the increase of activation state of 
astrocytes 24h after LPS treatment. We also performed western blotting using an anti-RPTPγ  
antibody made in rabbit (Rb-RPTPγ-P4) (Sorio et al. 1995), that revealed an increase, upon LPS 
treatment,  of  all  the  3  isoforms  detected:  the  full  length  RPTPγ  (180kDa  band)  and  two  truncated  
isoforms at 120 and 80kDa bearing the extracellular N-terminal portion that is recognized by the 
above mentioned antibody (Fig. 5 e). Interestingly, the densitometry revealed that after LPS the 
120 kDa band, increased much more than the others (180 kDa) (p<0,01 by t-test). Moreover the 
normalized expression level of the isoforms remained linearly correlated among the 3 individual 
mice, with a r2 from of 0.67 to 0.77 (Fig 5 g to i), suggesting that the smaller isoforms might 
derive from proteolytic cleavage of the longers. As gel loading control the Ponceau staining is also 
shown. 
We further confirmed that activated astrocytes express  high  levels  of  RPTPγ  in  another  model  
of   brain   inflammation:   the   5XFAD   mouse,   one   of   the   murine   models   of   Alzheimer’s   disease  
(Oakley et al. 2006). We stained cerebral sections of a 6 months old mouse in order to detect 
amyloid plaques in the cerebral cortex  by  using  the  4G8  antibody.  This  antibody  labels  amyloid  β  
and its precursors such as the neuronal Amyloid Precursor Protein (APP), which are ubiquitously 
expressed in neurons. For this reason many neurons are positive for 4G8 staining (Fig. 6). In tissue 
sections the amyloid plaques are clearly recognizable by their morphology. The strong activation 
of astrocytes and microglia around the amyloid plaques is visualized by the cell morphology 
(astrocytes here are bigger and present thick processes) and the elevation of the specific markers 
GFAP and Cd11b. Also, in this model of neuroinflammation, neurons and astrocytes were 
strongly  positive  for  RPTPγ.  On  the  contrary,  both  activated  microglial  cells  and  amyloid  plaques  
were negative. 
All  together  these  data  suggest  that  RPTPγ  is  generally  upregulated  during  neuroinflammation  
in vivo and might play a role in astrocyte activation. 
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Discussion 
 
In   this   study   we   investigated   the   distribution   of   RPTPγ   and   related   isoforms   in   the   nervous  
system by using, for the first time in the literature, simultaneously antibodies against C- and N-
terminus epitopes of the protein. These antibodies are able to distinguish between the full length 
(colocalization of C- and N- terminus) and the truncated isoforms lacking C-terminus domain 
(only N-terminus positivity) of the phosphatase. In line with previous studies (Lamprianou et al. 
2006),  we  found  a  predominant  and  widespread  neuronal  RPTPγ  immunopositivity  throughout  the  
brain. Using the C- and N-terminus antibodies, we further analyzed the  expression  of  RPTPγ:  both  
N- and C-terminus were found in the neuropil of cortical and hippocampal neurons demonstrating 
a  RPTPγ  full   length  expression. The positivity for the N-terminal domain was found also in the 
soma, often without its C-terminal counterpart showing an expression of a shorter isoform in the 
soma. Thus, at least two  isoforms  of  RPTPγ  are  present  in  the  adult  normal  murine  brain  and  are  
differentially distributed not only in different types of neurons, but also in different compartments 
of the same cell. Clarifying whether the truncated N-terminal isoforms are produced by alternative 
splicing or by proteolytic cleavage starting from the full-length protein, will be object of further 
studies. Indeed a proteolytic cleavage in vivo have been already hypothesized, but not yet 
demonstrated, studying   the   changes   in   RPTPγ   expression during mouse development in the 
superior colliculus: here three different isoforms were detected at different time points from E13 to 
P20 (Reinhard et al. 2009). 
It   was   reported   that   RPTPγ  KO  mice   did   not   show   any   obvious   phenotype,   displaying   only 
minor behavioral changes, in spite of the expression during development and in the adult brain in 
pyramidal   and   sensory   neurons   (Lamprianou   et   al.   2006;;   Zhang   et   al.,   2012).   Indeed  RPTPγ   is  
highly homologous to RPTPζ, and both are expressed in neurons (Shintani et al. 1998; Tanaka et 
al. 2003; Hayashi et al. 2005), suggesting that potentially they might have overlapping activities at 
the occurrence and RPTPζ,   could   compensate   the   loss   of   RPTPγ.   We   stained   our   sections  
simultaneously  for  RPTPγ  and  for  RPTPζ, and found only partial overlapping signals in neurons 
and, an overall different staining pattern. Beside supporting the specificity of the antibodies 
against the N-terminal  portion  of  RPTPγ  these  results  suggest  that  PTPs  other  than  RPTPζ might 
compensate for RPTPγ loss during the embryonal development of KO mice.  
This   report   supports   the   previous   studies   on   the   pattern   of   expression   of   RPTPγ   and   RPTPζ. 
Despite it is reported that RPTPζ is strongly expressed in glial cells (oligodendrocytes and 
astrocytes) we found a spotted-like positivity in cortical and hippocampal neurons, in line with 
previous studies that used the same antibodies (Hayashi et al. 2005), while   RPTPγ   had   a   very  
strong expression in neurons (Lamprianou et al, 2006). We show that most perivascular astrocytes 
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do  not  express  RPTPγ in normal adult mouse brain, and that in some sublocalisation of neurons 
both RPTPζ and  RPTPγ  can  be  detected. 
The  RPTPγ  role  and  function  in  the  adult  CNS  is unknown and largely unexplored, as well as 
are  its  ligands.  RPTPγ  could  putatively  bind to contactins-3, -4 and -5 that are widely distributed 
in the adult brain, but the meaning of this interaction is unclear (Bouyain and Watkins 2010; 
Lamprianou et al. 2011; Hendriks et al. 2013). Some  recent  data  support  a  function  of  RPTPγ  in  
depression (Zhang et al. 2012) and bipolar disorders (Hamshere et al. 2009). This is in line with its 
potential interaction with the CNTNs and CNTNs signaling pathway, which are genes mutated in 
mental disorders (Cottrel et al. 2011). 
In   chick   spinal   cord   RPTPγ   plays   a   role   in   spinal   cord   neurogenesis   during   embryonic  
development,   where   it   appears   to   influence   the  Wnt/β   catenin   signaling   and   neuronal   survival  
(Hashemi et al. 2011). Moreover  RPTPγ   inhibits   the  NGF-mediated neurite outgrowth in PC12 
cells  (Shintani  et  al.  2001).  Our  study  is  the  first  that  describes  the  distribution  of  different  RPTPγ  
isoforms in the brain, and it completes and enriches the current knowledge about the distribution 
of  RPTPγ  and  could  help  in  developing  new  hypotheses  about  its  role  and  molecular  mechanisms  
in neurons of the adult brain.  
Another major finding of our study is that, despite not being expressed in small astrocytes, 
RPTPγ   is  up-regulated in these same cells following intraperitoneal injection of LPS and in the 
5XFAD  murine  model   of   Alzheimer’s   disease,   two  well   characterized   in vivo models of brain 
inflammation. These data suggest, for the first time in vivo,   that  RPTPγ  can   be   involved   in   the 
process  of  astrocyte  activation.  It  is  already  known  that,  after  Interleukin  1  β  (IL1  β)  and  Tumor  
Necrosis   Factor   alpha   (TNFα)   treatment   in vitro,   RPTPγ   mRNA   is   upregulated   by   human  
astrocytoma cells (Schumann et al. 1998). Indeed after LPS ip treatment both   IL1  β   and  TNFα  
mRNA are upregulated in mouse brain within 90min, and the astrocyte activation reaches its 
maximum at 24h post injection (Kwon et al. 2010). In this study we showed that 24h after LPS 
injection the increase in GFAP level is accompanied by   the   increase   in  RPTPγ  protein   level   in  
brain astrocytes. This is the first time that this increase is demonstrated in vivo on different 
isoforms   of   RPTPγ.   Indeed,   we   observed   a   marked   increase   of   the   120   kDa   truncated   RPTPγ  
isoform by WB after LPS treatment. Since all isoforms present a reciprocal linear correlation, it 
might be possible that the truncated isoforms are produced in part by cleavage starting from the 
longer ones. Interestingly following LPS treatment, activated microglia and astrocytes are known 
to produce many different matrix metalloproteases like MMP-3 and MMP-9 (Gottschall and Deb 
1996; Lee et al. 2003). Cytokines  like  IL1  β  and  TNFα  are  potent  stimulant  of  MMPs  production  
by activated glia in vitro (Gottschall and Yu 1995; Crocker et al. 2006; for a review see 
Candelario-Jalil et al. 2009). The possible role of matrix metalloproteases in the cleavage of 
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RPTPγ  during  neuroinflammation  will  be  object  of  further  studies.  Indeed we cannot exclude that 
short and long isoforms are produced by alternative spicing, as happens for RPTP, that is highly 
homologous  to  RPTPγ. 
As concern the RPTP signal, we found a punctuate staining pattern in neurons, in line with 
previous studies where this protein was found to be localized post-synaptically and not in 
astrocytes when the same antibody was used (Hayashi et al. 2005; Kawachi et al. 1999). It has 
been reported for long time that RPTP is expressed in astrocytes (Canoll et al. 1996; Sakurai et 
al.1996;). Among the three splicing variants, its soluble isoform phosphacan lacking the 
intracellular domain is released during inflammation or lesion (Faissner et al. 2006). A possible 
explanation for this lack of positivity in astrocytes might be that mature astrocytes preferentially 
express the phosphacan isoform (Canoll 1996 et al.; Sakurai 1996 et al.), which is not detected by 
this antibody. 
More recent studies suggest that the neuronal RPTP isoforms might play a critical role in the 
reactive synaptogenesis occurring after injury (Harris et al., 2011). Indeed the last decade of 
research on Phosphacan/RPTP isoforms reveals a high degree of complexity in the regulation and 
roles of this particular phosphatase in both physiological and pathological conditions (Lamprianou 
et al. 2011; Hendriks et al. 2013). 
In   this  study,  we  show  an   increased  expression  of   the  RPTPγ isoform lacking the D2 domain 
upon   inflammation.   RPTPγ   inhibits  NGF signaling and therefore TRK dependent axon growth 
(Shintani 2001). Using different signaling pathways, RPTP and  RPTPγ   could   generate   similar  
biological function such as modulating neurite outgrowth during inflammation. The increased 
expression of the RPTPγ  isoform  lacking  a  C-terminal portion, likely including the D2 domain, is 
of interest. Indeed structural biology of PTPs proposed that these proteins homodimerize inducing 
inhibition of the phosphatase activity by changing the relative position of the D1 and D2 domains 
(Tremblay 2009; Barr et al. 2009). Thus, an isoform lacking the D2 domain could not be inhibited 
by this mechanism and could strengthen its efficacy to dephosphorylate the NGF/TRK signaling 
or other still unidentified pathways.  
In this line   both   phosphatase   RPTPγ   and   RPTP should increase in astrocytes when 
inflammation occurs. Indeed, as one of the main components of Condroitin Sulfate Proteoglycans 
(CSPGs), phosphacan is expressed at high level by reactive astrocytes upon injury, and prevent 
axon growth by direct binding to the surface of the growth cone and by interacting with 
L1/NgCAM/laminin   substrates   (for  a   review  see  Sandvig  et   al.,  2004).  RPTPγ   is  also  expressed  
upon cytokines treatment and inflammation. If both phosphatases have only partial overlap of 
expression, they might address similar biological function. 
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Overall,   our   study   enriches   the   current   knowledge   about   the   role   of   RPTPγ   in   astrocyte  
activation in vivo and   the  differential  distribution  of  RPTPγ   isoforms  could  help   in making new 
hypothesis about the mechanism of action/role of the phosphatase in neuronal physiological 
functions.  
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Figure Legends 
 
Fig.  1  RPTPγ  is  expressed  in  neurons  and  in  some astrocytes in the adult brain. 
Examples   of   immunostaining   showing   the   RPTPγ   positivity   of   neurons   (a-c), astrocytes and 
microglia (d-o).   Colocalization   of   RPTPγ   (green)   and   βIII-tubulin (blue) shows the neuronal 
expression  of  RPTPγ  in  the  cerebral  cortex (a-c). Astrocytes are labeled by GFAP (red). In a and c 
astrocytes surrounding a blood vessel are also shown (red). 
A  representative  image  of  the  dentate  gyrus  shows  the  mild  colocalization  of  RPTPγ  and  GFAP,  
indicating the positivity of some astrocytes in the hippocampus (d-f) as well as those surrounding 
some blood vessels (g-i). Small astrocytes (j-l)  are  negative  for  RPTPγ,  whereas  a  mild  positivity  
was found only in some big astrocytes (GFAP red in m) but not in the resting microglia labeled by 
CD11b (red in n and o). In some images the nuclear DAPI staining is also shown. Scale bars 50μm 
in a to f, 20μm in g to o.  
 
Fig.  2  RPTPγ  is  expressed  in  neurons  of  the  cerebellar  molecular  layer  and  in  cerebellar  
radial glia. 
Immunostaining  showing   the  RPTPγ expression in the cerebellar cortex of adult mouse brain. 
(a-d)  Colocalization  of  RPTPγ  (green)  and  βIII-tubulin (red) shows positivity for interneurons of 
the molecular layer, as well as Purkinje cell main dendrite. e-h.   Colocalization   of   RPTPγ   and  
GFAP (red) shows positivity for Bergmann radial glia. g and h are enlargements of the boxed 
region in f. (i-l)   Colocalization   of   RPTPγ   and   the   Bergmann   glia   specific   marker   S100   (red)  
confirms  the  expression  of  RPTPγ  in  these  cells.  k  is  an  enlargement  of  the  boxed region in j. In 
some images nuclei counterstaining by DAPI (blue) is also shown. ML: molecular layer; PL: 
Purkinje cell layer; GCL: granule cell layer. Scale bars 20μm in g, h, k, l, 40μm in all the other 
images. 
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Fig.  3  RPTPγ  C- and N-terminal epitopes are differently localized within brain cells. 
Immunostaining of brain sections by using different antibodies against either the N- (anti-
RPTPγ   chicken   isotype,   green)   or   the   C-terminal   (red)   portion   of   RPTPγ   allows   to   distinguish  
between the full length protein (colocalization) and a truncated isoform lacking the C-terminus 
epitope (green only). (a-b) cerebral cortex shows that the N- and C-terminus colocalizes in the 
apical dendrite and in some neurons, but the soma mainly presents the N-terminus positivity alone. 
(c-d) enlargements of the boxed region in a. (e-h) shows that resting astrocytes (GFAP, blue) are 
negative for both epitopes. (i-l) Cerebellar cortex displays C- and N- terminus colocalization only 
in Bergamnn radial glia, whereas the N-terminal epitope is present alone in Purkinje cells and 
colocalizes with Calbindin (blue). ML: molecular layer; PL: Purkinje cell layer. Scale bars 30μm 
in a, b, i, j, k, l; 15μm in c, d, e, f, g, h.  
 
Fig. 4 Comparison of the distribution of RPTPζ and  RPTPγ  receptors. 
Immunostaining of brain sections by using anti-RPTPγ   (antibody  made   in   chicken)   and   anti-
PTPζ, a protein that is highly homologous with RPTPγ.  a-f Cerebral cortex, where colocalization 
of  RPTPγ  (green)  and  RPTPζ,  (red)  occurs  in  the  neuropil  (βIII-tubulin, blue). f is an enlargement 
of the boxed region in d and shows the spotted staining pattern of RPTPζ. g-i In the hippocampus 
both proteins are neuronal. The boxed region enlarged in i shows astrocytes that are negative for 
PTPζ (arrows). j-l In the cerebellar cortex RPTPζ was found in Purkinje cell primary dendrites 
where  it  partially  colocalizes    with  RPTPγ. 
The different localizations and staining patterns of RPTPζ,   and   RPTPγ   further   support   the  
specificity of our N-terminal  antibodies  against  RPTPγ N-terminal domain. ML: molecular layer; 
PL: Purkinje cell layer. Scale bars 30μm. 
 
Fig.  5  RPTPγ  expression  increases  in  astrocytes  after  LPS  injection. 
RPTPγ   expression   in   mouse   brain   cortex   24h   after   LPS   i.p.   injection   was   assessed   by  
immunostaining and WB. (a-d)  Immunostaining  showing  a  strong  positivity  for  RPTPγ  (green)  in    
activated astrocytes (GFAP, red; colocalization yellow). The boxed region of a is enlarged in b, c 
and d, in order to highlight activated astrocytes surrounding a blood vessel. Scale bars 30μm. (e) 
WB of brain cortex lysates of 3 normal (-)  and  3  LPS  (+)  treated  mice.    Band  intensity  of  RPTPγ  
was detected by an antibody made in rabbit (rb-RPTPγ-P4). Bands at 180kDa show the full length 
protein isoform, whereas at 120 and 80 kDa we found two truncated isoforms. GFAP increase 
confirms the astrocyte activation after LPS injection. Ponceau staining was used for normalization 
of the loaded protein. The densitometry plot (f) shows the normalized band intensity relative to  
120 and 180kDa isoforms with or without LPS treatment. All isoforms increased after LPS 
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treatment,  especially  the  truncated  120kDa  RPTPγ.  p<0,01  by  t-test. (g-i) Plots showing the strong 
linear   correlation   between   the   normalized   intensities   of   the   3   RPTPγ   isoforms   showed   in e, 
suggesting their origin from a common precursor. 
 
Fig.   6   RPTPγ   is   expressed   in   cortical   activated   astrocytes   in   the   murine   model   of  
Alzheimer’s  disease. 
Expression  of  RPTPγ  (green)  was  assessed  in  brain  cortex  of  a  6  month  old  5xFAD  mouse  brain  
by immunostaining.  Staining  for  amyloid  β  peptide  (4G8,  red)  shows  neuronal  APP  and  amyloid  
plaques (red). (a-b)  RPTPγ  (green)  is  neuronal,  but  a  strong  positivity  was  found  also  in  astrocytes  
(GFAP, blue in a, red in b, false color). (c) shows the colocalization  of  RPTPγ  (green)  and  4G8  
(red) in neurons but not in amyloid plaques. (d-f) Activated microglia (CD11b, red) surrounding 
amyloid  plaques  is  negative  for  RPTPγ.  (f)  represents  an  enlargement  of  the  boxed  region  in  d.  (g-
i)  Neuronal  expression  of  RPTPγ   in  AD mice assessed by colocalization with MAP2 (blue in g 
and red in h, false color). Scale bars 40 μm in a-e, 20 μm in f-i.    
 
Supplementary figure  
As an additional test for antibody specificity we stained some slides from one heterozygous and 
one   RPTPγ  KO mouse using the two antibodies against the N- (ch-RPTP, green) and the C-
terminus (goat-RPTP, red) epitopes of the phosphatase. Cerebral cortex (A-F and J-O) and 
hippocampus (G-I and P-R) showed a strong decrease of RPTP signal in the KO (J to R) in 
comparison to the heterozygous (A to I). A residual staining was still present in some regions, in 
particular in the granular layer of the hippocampus, a region known to be prone to aspecific 
staining. Scale bars 50m. 
 
Table 1  
Schematic representation of the antibodies  used  against  RPTPγ.  Epitopes: amino acid number of 
epitopes, validated application: IP= immuno-precipitation, WB= western blot, IHC= immuno histo 
chemistry,   Flow=   flow   cytometry,   IF=   immuno   fluorescence.   The   RPTPγ   structure   scheme    
displays where the epitopes are localized within the predicted protein sequence of the 4 different 
isoforms. CA: Carbonic anhydrase-like; FNIII: Fibronectin type III-like domain; TM: 
transmembrane portion; D1: active phosphatase domain and D2: inactive phosphatase domain.  
 
 Table 2 
Distribution  of  RPTPγ  positivity  in  mouse  brain  coronal  sections,  assessed  by  immunostaining  
and fluorescence microscopy.  
 14 
References 
 
Barnea G, Silvennoinen O, Shaanan B, Honegger AM, Canoll PD, D'Eustachio P, Morse B, 
Levy JB, Laforgia S, Huebner K, et al. (1993) Identification of a carbonic anhydrase-like 
domain in the extracellular region of RPTP gamma defines a new subfamily of receptor 
tyrosine phosphatases. Mol Cell Biol 13 (3):1497-1506 
Barr, A. J., Ugochukwu, E., Lee, W. H., King, O. N., Filippakopoulos, P., Alfano, I., et al. 
(2009). Large-scale structural analysis of the classical human protein tyrosine 
phosphatome. [Research Support, Non-U.S. Gov't]. Cell, 136(2), 352-363, 
doi:10.1016/j.cell.2008.11.038. 
Bouyain S, Watkins DJ (2010) The protein tyrosine phosphatases PTPRZ and PTPRG bind to 
distinct members of the contactin family of neural recognition molecules. Proc Natl Acad 
Sci U S A 107 (6):2443-2448. doi:0911235107 [pii] 
10.1073/pnas.0911235107 
Candelario-Jalil E, Yang Y, Rosenberg GA (2009) Diverse roles of matrix metalloproteinases 
and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. 
Neuroscience 158 (3):983-994. doi:S0306-4522(08)00895-6 [pii] 
10.1016/j.neuroscience.2008.06.025 
Canoll, P. D., Petanceska, S., Schlessinger, J., & Musacchio, J. M. (1996). Three forms of 
RPTP-beta are differentially expressed during gliogenesis in the developing rat brain and 
during glial cell differentiation in culture. [Research Support, U.S. Gov't, P.H.S.]. J 
Neurosci Res, 44(3), 199-215, doi:10.1002/(SICI)1097-4547(19960501)44:3&lt;199::AID-
JNR1&gt;3.0.CO;2-B. 
Cottrell, C. E., Bir, N., Varga, E., Alvarez, C. E., Bouyain, S., Zernzach, R., et al. (2011). 
Contactin 4 as an autism susceptibility locus. [Case Reports Research Support, N.I.H., 
Extramural Research Support, U.S. Gov't, Non-P.H.S.]. Autism Res, 4(3), 189-199, 
doi:10.1002/aur.184. 
Crocker SJ, Milner R, Pham-Mitchell N, Campbell IL (2006) Cell and agonist-specific 
regulation of genes for matrix metalloproteinases and their tissue inhibitors by primary glial 
cells. J Neurochem 98 (3):812-823. doi:JNC3927 [pii] 
10.1111/j.1471-4159.2006.03927.x 
Dabrowski A, Umemori H (2011) Orchestrating the synaptic network by tyrosine 
phosphorylation signalling. J Biochem 149 (6):641-653. doi:mvr047 [pii] 
10.1093/jb/mvr047 
 15 
Della Peruta M, Martinelli G, Moratti E, Pintani D, Vezzalini M, Mafficini A, Grafone T, 
Iacobucci I, Soverini S, Murineddu M, Vinante F, Tecchio C, Piras G, Gabbas A, Monne 
M, Sorio C (2010) Protein tyrosine phosphatase receptor type {gamma} is a functional 
tumor suppressor gene specifically downregulated in chronic myeloid leukemia. Cancer 
research 70 (21):8896-8906. doi:10.1158/0008-5472.CAN-10-0258 
Faissner A, Heck N, Dobbertin A, Garwood J (2006) DSD-1-Proteoglycan/Phosphacan and 
receptor protein tyrosine phosphatase-beta isoforms during development and regeneration 
of neural tissues. Adv Exp Med Biol 557:25-53. doi:10.1007/0-387-30128-3_3 
Gottschall PE, Deb S (1996) Regulation of matrix metalloproteinase expressions in 
astrocytes, microglia and neurons. Neuroimmunomodulation 3 (2-3):69-75 
Gottschall PE, Yu X (1995) Cytokines regulate gelatinase A and B (matrix metalloproteinase 
2 and 9) activity in cultured rat astrocytes. J Neurochem 64 (4):1513-1520 
Hamshere, M. L., Green, E. K., Jones, I. R., Jones, L., Moskvina, V., Kirov, G., et al. (2009). 
Genetic utility of broadly defined bipolar schizoaffective disorder as a diagnostic concept. 
[Comparative Study Research Support, Non-U.S. Gov't]. Br J Psychiatry, 195(1), 23-29, 
doi:10.1192/bjp.bp.108.061424. 
Harris, J. L., Reeves, T. M., & Phillips, L. L. (2011). Phosphacan and receptor protein 
tyrosine phosphatase beta expression mediates deafferentation-induced synaptogenesis. 
[Research Support, N.I.H., Extramural]. Hippocampus, 21(1), 81-92, 
doi:10.1002/hipo.20725. 
Hashemi H, Hurley M, Gibson A, Panova V, Tchetchelnitski V, Barr A, Stoker AW (2011) 
Receptor tyrosine phosphatase PTPgamma is a regulator of spinal cord neurogenesis. Mol 
Cell Neurosci 46 (2):469-482. doi:S1044-7431(10)00263-0 [pii] 
10.1016/j.mcn.2010.11.012 
Hayashi N, Oohira A, Miyata S (2005) Synaptic localization of receptor-type protein tyrosine 
phosphatase zeta/beta in the cerebral and hippocampal neurons of adult rats. Brain Res 
1050 (1-2):163-169. doi:S0006-8993(05)00787-0 [pii] 
10.1016/j.brainres.2005.05.047 
Hendriks, W. J., Elson, A., Harroch, S., Pulido, R., Stoker, A., & den Hertog, J. (2013). 
Protein tyrosine phosphatases in health and disease. FEBS J, 280(2), 708-730, 
doi:10.1111/febs.12000. 
Johnson KG, Van Vactor D (2003) Receptor protein tyrosine phosphatases in nervous system 
development. Physiol Rev 83 (1):1-24. doi:10.1152/physrev.00016.2002 
 16 
Kawachi, H., Tamura, H., Watakabe, I., Shintani, T., Maeda, N., & Noda, M. (1999). Protein 
tyrosine phosphatase zeta/RPTPbeta interacts with PSD-95/SAP90 family. [Research 
Support, Non-U.S. Gov't]. Brain Res Mol Brain Res, 72(1), 47-54. 
Kwon MS, Seo YJ, Choi SM, Won MH, Lee JK, Park SH, Jung JS, Sim YB, Suh HW (2010) 
The time-dependent effect of lipopolysaccharide on kainic acid-induced neuronal death in 
hippocampal CA3 region: possible involvement of cytokines via glucocorticoid. 
Neuroscience 165 (4):1333-1344. doi:S0306-4522(09)01971-X [pii] 
10.1016/j.neuroscience.2009.11.060 
Lamprianou S, Chatzopoulou E, Thomas JL, Bouyain S, Harroch S (2011) A complex 
between contactin-1 and the protein tyrosine phosphatase PTPRZ controls the development 
of oligodendrocyte precursor cells. Proc Natl Acad Sci U S A 108 (42):17498-17503. 
doi:1108774108 [pii] 
10.1073/pnas.1108774108 
Lamprianou S, Harroch S (2006) Receptor protein tyrosine phosphatase from stem cells to 
mature glial cells of the central nervous system. J Mol Neurosci 29 (3):241-255. 
doi:JMN:29:3:241 [pii] 
10.1385/JMN:29:3:241 
Lamprianou S, Vacaresse N, Suzuki Y, Meziane H, Buxbaum JD, Schlessinger J, Harroch S 
(2006) Receptor protein tyrosine phosphatase gamma is a marker for pyramidal cells and 
sensory neurons in the nervous system and is not necessary for normal development. Mol 
Cell Biol 26 (13):5106-5119. doi:26/13/5106 [pii] 
10.1128/MCB.00101-06 
Lee WJ, Shin CY, Yoo BK, Ryu JR, Choi EY, Cheong JH, Ryu JH, Ko KH (2003) Induction 
of matrix metalloproteinase-9 (MMP-9) in lipopolysaccharide-stimulated primary 
astrocytes is mediated by extracellular signal-regulated protein kinase 1/2 (Erk1/2). Glia 41 
(1):15-24. doi:10.1002/glia.10131 
Mafficini A, Vezzalini M, Zamai L, Galeotti L, Bergamini G, Della Peruta M, Melotti P, 
Sorio C (2007) Protein Tyrosine Phosphatase Gamma (PTPgamma) is a Novel Leukocyte 
Marker Highly Expressed by CD34 Precursors. Biomark Insights 2:218-225 
Nishiwaki T, Maeda N, Noda M (1998) Characterization and developmental regulation of 
proteoglycan-type protein tyrosine phosphatase zeta/RPTPbeta isoforms. J Biochem 123 
(3):458-467 
Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, 
Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal beta-amyloid 
aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial 
 17 
Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26 
(40):10129-10140. doi:26/40/10129 [pii] 
10.1523/JNEUROSCI.1202-06.2006 
Reinhard J, Horvat-Brocker A, Illes S, Zaremba A, Knyazev P, Ullrich A, Faissner A (2009) 
Protein tyrosine phosphatases expression during development of mouse superior colliculus. 
Exp Brain Res 199 (3-4):279-297. doi:10.1007/s00221-009-1963-6 
Romero-Calvo I, Ocon B, Martinez-Moya P, Suarez MD, Zarzuelo A, Martinez-Augustin O, 
de Medina FS (2010) Reversible Ponceau staining as a loading control alternative to actin 
in Western blots. Anal Biochem 401 (2):318-320. doi:S0003-2697(10)00135-1 [pii] 
10.1016/j.ab.2010.02.036 
Sakurai, T., Friedlander, D. R., & Grumet, M. (1996). Expression of polypeptide variants of 
receptor-type protein tyrosine phosphatase beta: the secreted form, phosphacan, increases 
dramatically during embryonic development and modulates glial cell behavior in vitro. 
[Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. J Neurosci Res, 
43(6), 694-706, doi:10.1002/(SICI)1097-4547(19960315)43:6&lt;694::AID-
JNR6&gt;3.0.CO;2-9. 
Sandvig, A., Berry, M., Barrett, L. B., Butt, A., & Logan, A. (2004). Myelin-, reactive glia-, 
and scar-derived CNS axon growth inhibitors: expression, receptor signaling, and 
correlation with axon regeneration. [Review]. Glia, 46(3), 225-251, 
doi:10.1002/glia.10315. 
Schumann G, Fiebich BL, Menzel D, Hull M, Butcher R, Nielsen P, Bauer J (1998) Cytokine-
induced transcription of protein-tyrosine-phosphatases in human astrocytoma cells. Brain 
Res Mol Brain Res 62 (1):56-64. doi:S0169328X9800237X [pii] 
Shintani T, Maeda N, Nishiwaki T, Noda M (1997) Characterization of rat receptor-like 
protein tyrosine phosphatase gamma isoforms. Biochem Biophys Res Commun 230 
(2):419-425. doi:S0006-291X(96)95973-2 [pii] 
10.1006/bbrc.1996.5973 
Shintani T, Maeda N, Noda M (2001) Receptor-like protein tyrosine phosphatase gamma 
(RPTPgamma), but not PTPzeta/RPTPbeta, inhibits nerve-growth-factor-induced neurite 
outgrowth in PC12D cells. Dev Neurosci 23 (1):55-69. doi:48696 [pii] 
Shintani T, Watanabe E, Maeda N, Noda M (1998) Neurons as well as astrocytes express 
proteoglycan-type protein tyrosine phosphatase zeta/RPTPbeta: analysis of mice in which 
the PTPzeta/RPTPbeta gene was replaced with the LacZ gene. Neurosci Lett 247 (2-3):135-
138 
 18 
Sorio C, Mendrola J, Lou Z, LaForgia S, Croce CM, Huebner K (1995) Characterization of 
the receptor protein tyrosine phosphatase gene product PTP gamma: binding and activation 
by triphosphorylated nucleosides. Cancer Res 55 (21):4855-4864 
Tanaka M, Maeda N, Noda M, Marunouchi T (2003) A chondroitin sulfate proteoglycan 
PTPzeta /RPTPbeta regulates the morphogenesis of Purkinje cell dendrites in the 
developing cerebellum. J Neurosci 23 (7):2804-2814. doi:23/7/2804 [pii] 
Tonks NK (2006) Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev 
Mol Cell Biol 7 (11):833-846. doi:nrm2039 [pii] 
10.1038/nrm2039 
Tremblay, M. L. (2009). The PTP family photo album. [Comment]. Cell, 136(2), 213-214, 
doi:10.1016/j.cell.2009.01.006. 
Vezzalini M, Mombello A, Menestrina F, Mafficini A, Della Peruta M, van Niekerk C, 
Barbareschi M, Scarpa A, Sorio C (2007) Expression of transmembrane protein tyrosine 
phosphatase gamma (PTPgamma) in normal and neoplastic human tissues. Histopathology 
50 (5):615-628. doi:HIS2661 [pii] 
10.1111/j.1365-2559.2007.02661.x 
Zhang W, Savelieva K V, Tran D, Pogorelov V M, Cullinan E B, Backer K B, Platt K A, Hu 
S, Rajan I, Xu N, Lanthorn T H (2012) Characterization of PTPRG in knockdown and 
phosphatase-inactive mutant mice and substrate trapping analysis of PTPRG in mammalian 
cells. Plos One 7 (9) e45500. doi:10.1371/journal.pone.0045500 
 
)LJXUH
&OLFNKHUHWRGRZQORDGKLJKUHVROXWLRQLPDJH
)LJXUH
&OLFNKHUHWRGRZQORDGKLJKUHVROXWLRQLPDJH
)LJXUH
&OLFNKHUHWRGRZQORDGKLJKUHVROXWLRQLPDJH
)LJXUH
&OLFNKHUHWRGRZQORDGKLJKUHVROXWLRQLPDJH
)LJXUH
&OLFNKHUHWRGRZQORDGKLJKUHVROXWLRQLPDJH
)LJXUH
&OLFNKHUHWRGRZQORDGKLJKUHVROXWLRQLPDJH
An#body( Class( Epitope((
Homology(
human7
mouse(
Sequence( Validated(applica#on(
Chicken(PTPRG*(( IgY( 390'408*( 100%* CZNEDEKEKTFTKDSDKDLK*(
IP,*WB,*IHC,*
Flow(
Rabbit(PTPRG7(P4(
**( IgG(
687'710*
(
96%*
(h'K*/*m'R*)****
CGSDPKRPEMPSKKP
MSRGDRFSED*!
IP,*WB,*IHC,*
Flow(
Goat(PTPRG((C718):(
sc71111( IgG( C'term(
Cross*reacPvity*
Human'mouse'
rat*
SANTA*CRUZ*
BIOTECHNOLOGY,*
INC.(
WB,*IF(
Table1. Antibodies and schematic localization of epitopes on the different RPTPγ  isoforms!
 
* : Mafficini A et al., (2007) 
Biomarker Insights 2:218-225 
**: Sorio C et al., (1995) Cancer 
Res. 55 (21):4855-4864, 
Vezzalini M et al., (2007) 
Histopathology 50 (5):615-628 
***: same class substitution: 
human K (Lys)! mouse R(Arg) 
 
TM 
D1 
D2 
CA 
FNIII 
C-term 
N-term 
TM 
D1 
D2 
CA 
FNIII 
C-term 
N-term 
TM 
D1 
CA 
FNIII 
N-term 
CA 
FNIII 
N-term 
RPTPγ -A            B          C    S 
7DEOH
!Distribution!of!RPTP!positivity!in!mouse!brain!
!
Structure/nucleus type of positive cells positivity cellular localization
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CA1 hippocampus neurons +++ perisomatic+neuropile
CAT!cortico!amigdaloid transition zone +++ perisomatic+neuropile
cc corpus callosum !
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Mo!motory I neurons layer 2+3!5!6 +++ perisomatic+neuropile
MO!motory II neurons layer 2+3!5!6 +++ perisomatic+neuropile
PIR!pyriform cortex neurons layer 2+3 +++ perisomatic+neuropile
SFO subfornical organ +
SSP!somatosensory I neurons layers 2!3!4!5!6 +++ perisomatic+neuropile
TRS triangular Nucleus of septum neurons ++ soma
ventral hippocampal commissure glia + perisomatic
VISC!visceral cortical area +++ perisomatic+neuropile
THALAMUS AD anterodorsal nucleus neurons +++ soma
ac anterior commissure !
AM anteromedial nucleus neurons + soma
small cells !
AV anteroventral nucleus neurons + soma
BLA! basolateral nucleus of amygdala ++ perisomatic+neuropile
BSTad bed Nu of stria terminalis, anterodorsal neurons ++ perisomatic+neuropile
BSTov bed Nu of stria terminalis, oval part neurons +++ perisomatic+neuropile
CEA!central nucleus of amygdala +++ cytoplasm+neuropile
CM!central medial Nu +++ perisomatic+neuropile
CP striatum neurons ++ perisomatic
smallQunidentifiedQcells
fi!fimbria + maybe some glial cell
fx fornix !
GPI globus pallidus lateralis neurons +++ cytoplasm+some dendrites
smallQunidentifiedQcells
IAM! interanteromedial nu +++ perisomatic+neuropile
int internal capsule glia? +
LD laterodorsal nu neurons ++ soma
Lsd lateral septum Nu, dorsal neurons +++ perisomatic+neuropile
Lsi lateral septum Nu, intermediate neurons perisomatic+neuropile
LSv lateral septum Nu, ventral neurons ++ perisomatic+neuropile
MD! mediodorsal Nu neurons maybe some glial cell +++ perisomatic
MEPO median preoptic Nu !
MH medial habenula neurons +++ cytoplasm
PVT!periventricular Nu ++
RE!reuniens Nu ++ perisomatic+neuropile
RT reticular Nu neurons +++ cytoplasm
small cells !
sm stria medullaris glia? +++
st stria terminalis !
VA ventral anterior Nu +/!
VAL!ventral anterolateral Nu neurons +++ perisomatic+neuropile
VPL! ventroposterolateral Nu neurons +++ perisomatic+neuropile
XI!xiphoid Nu !
HYPOTHALAMUS AHN!anterior hypothalamic Nu neurons ++ perisomatic+neuropile
ARH arcuate Nu neurons ++
AVP anteroventral preoptic Nu !
AVPV anteroventral periventricular Nu +
LHA!lateral hypothalamic area +
lot! lateral olfactory tract ! someQglialQcell
MEAd! medial nu of amygdala neurons +++
MPNl! medial preoptic nu, lateral +
MPO!medial preoptic area !
opt!optic tract some glial cells +/!
OT olfactory tubercle neurons ++
PVH periventricular Nu neurons ++
PVH!paraventricular Nu neurons + perisomatic+neuropil
RE reuniens Nu neurons ++
SI substantia innominata neurons ++
SO supraoptic Nu neurons +++
BRAINSTEM CNgl ! coclear Nu, granular layer +
GRN ! gigantocellular reticular Nu neurons +++ cytoplasm+neuropil
smallQunidentifiedQcells
icp ! inferior cerebellar peduncle +++ axons
IRN ! intermediate reticular Nu +++ cytoplasm+neuropil
LVN ! lateral vestibular Nu neurons +++ cytoplasm+neuropil
smallQunidentifiedQcells +++
MARN ! magnocellular reticular Nu neurons +++ cytoplasm+neuropil
mlf ! medial longitudinal fasciculus !
ml ! medial lemniscus !
PARN ! parvicellular reticular nucleus +++ cytoplasm+neuropil
PGRNd ! paragigantocellular reticular nucleus dorsal neurons +++ cytoplasm+neuropil
smallQunidentifiedQcells
PGRNI ! paragigantocellular reticular nucleus neurons +++ cytoplasm+neuropil
smallQunidentifiedQcells !
PPY ! peripyramidal Nu neurons +
smallQunidentifiedQcells
PRP ! Nu prepositus neurons ++ cytoplasm+neuropil
smallQunidentifiedQcells ++
py ! piramidal tract smallQunidentifiedQcells ! maybe some glial cells
RM ! Nu raphe magnus neurons +++ cytoplasm+neuropil
RPA ! Nu raphe pallidus !
rust ! rubrospinal tract !
SPVOdm ! spinal Nu of the trigeminal nerve neurons +++ cytoplasm+neuropil
smallQunidentifiedQcells
SPVOvl ! spinal Nu of the trigeminal nerve neurons +++ cytoplasm+neuropil
smallQunidentifiedQcells !
spV!spinal tract of trigeminal nerve smallQunidentifiedQcells !
tb ! trapezoid body smallQunidentifiedQcells !
VCO ! ventral coclear nucleus neurons +++ cytoplasm+neuropil
smallQunidentifiedQcells
VII ! nu faciale neurons +++ cytoplasm+neuropil
smallQunidentifiedQcells +++
vsc ! ventral spinocerebellar tract
vVIIIn ! vestibulo!coclear nerve, vestibular root smallQunidentifiedQcells + axons
CEREBELLUM DN!dentate Nu neurons +++ cytoplasm+neuropil
smallQunidentifiedQcells
DNp!dentate Nu parvicellular part neurons +++ cytoplasm+neuropil
FN fastigial Nu neurons +++ cytoplasm+neuropil
smallQunidentifiedQcells
IP!interposit Nu neurons +++ cytoplasm+neuropil
smallQunidentifiedQcells
SVN!superior vestibular Nu neurons +++ cytoplasm+neuropil
smallQunidentifiedQcells
VCN!vestibulocerebeccar Nu neurons +++ cytoplasm+neuropil
smallQunidentifiedQcells
Molecular layer Bergmann glia +++ cytoplasm+neuropil
granule cells +/9!!!!!!!!!!!!!!uncertain
Purkinje neurons + soma
!
!
and!main!dendrite
!
!
!
Interneurons!molecular!layer! ! !!!!!!!!!!! ! !!!!!!!!!!+!!! !!!soma
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